Apellis Pharmaceuticals's market cap is currently $3.51B. The company's EPS TTM is $-2.037; its P/E ratio is ―; Apellis Pharmaceuticals is scheduled to report earnings on March 4, 2025, and the estimated EPS forecast is $-0.37. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 396.59M	$ 75.42M	$ 66.56M	$ 250.65M	$ 0.00
Gross Profit	$ 338.08M	$ 69.79M	$ 61.36M	$ 225.60M	$ -288.02M
Operating Income	$ -517.12M	$ -594.61M	$ -536.28M	$ -213.73M	$ -288.02M
EBITDA	$ -495.21M	$ -617.39M	$ -731.27M	$ -312.23M	$ -298.83M
Net Income	$ -528.63M	$ -652.17M	$ -746.35M	$ -344.87M	$ -309.82M
Balance Sheet
Cash & Short-Term Investments	$ 352.30M	$ 551.80M	$ 700.55M	$ 877.65M	$ 351.99M
Total Assets	$ 788.73M	$ 760.22M	$ 881.76M	$ 960.57M	$ 389.24M
Total Debt	$ 110.93M	$ 112.71M	$ 210.22M	$ 377.73M	$ 157.03M
Net Debt	$ -240.26M	$ -439.09M	$ -429.97M	$ -188.05M	$ -194.95M
Total Liabilities	$ 594.21M	$ 590.35M	$ 683.10M	$ 756.01M	$ 355.02M
Stockholders' Equity	$ 194.52M	$ 169.87M	$ 198.66M	$ 204.56M	$ 34.23M
Cash Flow
Free Cash Flow	$ -595.51M	$ -515.27M	$ -564.23M	$ -165.91M	$ -212.83M
Operating Cash Flow	$ -594.74M	$ -513.75M	$ -563.13M	$ -160.49M	$ -211.14M
Investing Cash Flow	$ -674.00K	$ 59.89M	$ 247.62M	$ -316.99M	$ -1.69M
Financing Cash Flow	$ 394.50M	$ 365.66M	$ 392.24M	$ 692.18M	$ 388.54M

Currency in USD

Apellis Pharmaceuticals Earnings and Revenue History

Income Statement >

Apellis Pharmaceuticals Debt to Assets

Balance Sheet >

Apellis Pharmaceuticals Cash Flow

Cash Flow >

Apellis Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing